vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and EnerSys (ENS). Click either name above to swap in a different company.

EnerSys is the larger business by last-quarter revenue ($919.1M vs $487.7M, roughly 1.9× CLOVER HEALTH INVESTMENTS, CORP.). EnerSys runs the higher net margin — 9.8% vs -10.1%, a 19.9% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 1.4%). EnerSys produced more free cash flow last quarter ($171.3M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 0.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

EnerSys is a stored energy systems and technology provider for industrial applications. The company manufactures reserve-power and motive-power batteries, battery chargers, power equipment, battery accessories and outdoor equipment enclosures.

CLOV vs ENS — Head-to-Head

Bigger by revenue
ENS
ENS
1.9× larger
ENS
$919.1M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+43.3% gap
CLOV
44.7%
1.4%
ENS
Higher net margin
ENS
ENS
19.9% more per $
ENS
9.8%
-10.1%
CLOV
More free cash flow
ENS
ENS
$240.2M more FCF
ENS
$171.3M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
0.5%
ENS

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CLOV
CLOV
ENS
ENS
Revenue
$487.7M
$919.1M
Net Profit
$-49.3M
$90.4M
Gross Margin
30.1%
Operating Margin
-10.1%
13.5%
Net Margin
-10.1%
9.8%
Revenue YoY
44.7%
1.4%
Net Profit YoY
-123.2%
-21.3%
EPS (diluted)
$2.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
ENS
ENS
Q4 25
$487.7M
$919.1M
Q3 25
$496.6M
$951.3M
Q2 25
$477.6M
$893.0M
Q1 25
$462.3M
$974.8M
Q4 24
$337.0M
$906.2M
Q3 24
$331.0M
$883.7M
Q2 24
$356.3M
$852.9M
Q1 24
$346.9M
$910.7M
Net Profit
CLOV
CLOV
ENS
ENS
Q4 25
$-49.3M
$90.4M
Q3 25
$-24.4M
$68.4M
Q2 25
$-10.6M
$57.5M
Q1 25
$-1.3M
$96.5M
Q4 24
$-22.1M
$114.8M
Q3 24
$-9.2M
$82.3M
Q2 24
$7.4M
$70.1M
Q1 24
$-19.2M
$60.9M
Gross Margin
CLOV
CLOV
ENS
ENS
Q4 25
30.1%
Q3 25
29.1%
Q2 25
28.4%
Q1 25
31.2%
Q4 24
32.9%
Q3 24
24.5%
28.5%
Q2 24
30.3%
27.9%
Q1 24
23.6%
27.9%
Operating Margin
CLOV
CLOV
ENS
ENS
Q4 25
-10.1%
13.5%
Q3 25
-4.9%
9.7%
Q2 25
-2.2%
9.7%
Q1 25
-0.3%
13.5%
Q4 24
-6.4%
15.7%
Q3 24
-2.7%
11.2%
Q2 24
2.0%
10.7%
Q1 24
-6.5%
8.9%
Net Margin
CLOV
CLOV
ENS
ENS
Q4 25
-10.1%
9.8%
Q3 25
-4.9%
7.2%
Q2 25
-2.2%
6.4%
Q1 25
-0.3%
9.9%
Q4 24
-6.6%
12.7%
Q3 24
-2.8%
9.3%
Q2 24
2.1%
8.2%
Q1 24
-5.5%
6.7%
EPS (diluted)
CLOV
CLOV
ENS
ENS
Q4 25
$2.40
Q3 25
$1.80
Q2 25
$1.46
Q1 25
$2.39
Q4 24
$2.88
Q3 24
$2.01
Q2 24
$1.71
Q1 24
$1.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
ENS
ENS
Cash + ST InvestmentsLiquidity on hand
$78.3M
$450.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$1.9B
Total Assets
$541.0M
$4.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
ENS
ENS
Q4 25
$78.3M
$450.1M
Q3 25
$388.6M
Q2 25
$346.7M
Q1 25
$343.1M
Q4 24
$194.5M
$463.2M
Q3 24
$288.0M
$407.9M
Q2 24
$254.8M
$344.1M
Q1 24
$208.3M
$333.3M
Total Debt
CLOV
CLOV
ENS
ENS
Q4 25
Q3 25
Q2 25
Q1 25
$1.1B
Q4 24
Q3 24
Q2 24
Q1 24
$802.0M
Stockholders' Equity
CLOV
CLOV
ENS
ENS
Q4 25
$308.7M
$1.9B
Q3 25
$340.9M
$1.9B
Q2 25
$344.2M
$1.9B
Q1 25
$336.1M
$1.9B
Q4 24
$341.1M
$1.8B
Q3 24
$342.2M
$1.8B
Q2 24
$324.9M
$1.8B
Q1 24
$292.5M
$1.8B
Total Assets
CLOV
CLOV
ENS
ENS
Q4 25
$541.0M
$4.0B
Q3 25
$559.7M
$4.1B
Q2 25
$575.0M
$4.1B
Q1 25
$583.7M
$4.0B
Q4 24
$580.7M
$4.0B
Q3 24
$653.0M
$4.0B
Q2 24
$674.2M
$3.6B
Q1 24
$671.8M
$3.5B
Debt / Equity
CLOV
CLOV
ENS
ENS
Q4 25
Q3 25
Q2 25
Q1 25
0.57×
Q4 24
Q3 24
Q2 24
Q1 24
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
ENS
ENS
Operating Cash FlowLast quarter
$-66.9M
$184.6M
Free Cash FlowOCF − Capex
$-69.0M
$171.3M
FCF MarginFCF / Revenue
-14.1%
18.6%
Capex IntensityCapex / Revenue
0.4%
1.4%
Cash ConversionOCF / Net Profit
2.04×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$441.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
ENS
ENS
Q4 25
$-66.9M
$184.6M
Q3 25
$12.1M
$218.0M
Q2 25
$5.4M
$968.0K
Q1 25
$-16.3M
$135.2M
Q4 24
$34.8M
$81.1M
Q3 24
$50.0M
$33.6M
Q2 24
$44.8M
$10.4M
Q1 24
$25.9M
Free Cash Flow
CLOV
CLOV
ENS
ENS
Q4 25
$-69.0M
$171.3M
Q3 25
$11.4M
$197.1M
Q2 25
$4.8M
$-32.1M
Q1 25
$-16.5M
$104.9M
Q4 24
$33.3M
$56.8M
Q3 24
$49.6M
$3.3M
Q2 24
$44.4M
$-25.7M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
ENS
ENS
Q4 25
-14.1%
18.6%
Q3 25
2.3%
20.7%
Q2 25
1.0%
-3.6%
Q1 25
-3.6%
10.8%
Q4 24
9.9%
6.3%
Q3 24
15.0%
0.4%
Q2 24
12.5%
-3.0%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
ENS
ENS
Q4 25
0.4%
1.4%
Q3 25
0.1%
2.2%
Q2 25
0.1%
3.7%
Q1 25
0.0%
3.1%
Q4 24
0.5%
2.7%
Q3 24
0.1%
3.4%
Q2 24
0.1%
4.2%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
ENS
ENS
Q4 25
2.04×
Q3 25
3.19×
Q2 25
0.02×
Q1 25
1.40×
Q4 24
0.71×
Q3 24
0.41×
Q2 24
6.04×
0.15×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

ENS
ENS

Energy Systems$399.5M43%
Motive Power$352.0M38%
Services$92.6M10%
Transferred Over Time$38.2M4%
Other$36.8M4%

Related Comparisons